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The prevailing theory regarding the development of endometrial
cancer is the ‘unopposed oestrogen’ theory, that proposes that
endometrial cancer risk is increased by exposure to oestrogens
unopposed by progesterone and that this increased risk is a result
of increased mitotic activity of the endometrium (Siiteri, 1978;
Henderson et al, 1982). The theory is based on epidemiologic
observations, as well as observations on the hormonal regulation
of endometrial cell mitoses during normal menstrual cycles. The
endometrial cell division rate appears to be maximally stimulated
by the low levels of oestradiol found in the early follicular phase
and to be effectively zero in the presence of luteal phase proges-
terone (Ferenczy et al, 1979). 
The unopposed oestrogen hypothesis successfully explains
many of the epidemiologic features of the disease, such as the
increased risks associated with oestrogen-secreting tumours, and
with use of oestrogen replacement therapy. The hypothesis is also
consistent with the reduction in risk observed with use of
combined oral contraceptives, which are associated with minimal
endometrial exposure to unopposed oestrogens and rare cell
division. In addition, the unopposed oestrogen hypothesis provides
a plausible mechanism for postmenopausal obesity, which, with
oestrogen replacement therapy, is the most important risk
factor for endometrial cancer. Production of oestrogens through
aromatization of androgens in peripheral tissues, particularly in
adipose tissue, is the main source of oestrogens in postmenopausal
women. 
Whereas the role of exogenous oestrogens in the development
of endometrial cancer is well established, less epidemiologic
evidence is available regarding the role of endogenous oestrogens,
in particular at the physiologically low levels observed after
menopause. An upper limit has been proposed by Key and Pike,
(1988) beyond which oestradiol unopposed by progesterone does
not induce any further increase in mitotic rate, and estimated this
limit to be 50 pg ml–1, the upper limit of oestradiol during the early
follicular phase of the menstrual cycle. After menopause, levels of
oestradiol are well below this level, in the range of 5 to 20 pg ml–1,
and progesterone levels are also low, 40 ng dl–1 or less. According
to the Key and Pike hypothesis, one would therefore expect post-
menopausal serum levels of oestrogens to be associated with risk
of endometrial cancer. 
A number of case–control studies have examined the associa-
tion of endogenous oestrogen levels with endometrial cancer risk
(Aleem et al, 1976; Benjamin and Deutsch, 1976; Judd et al, 1976,
1980; Nisker et al, 1980; Davidson et al, 1981; von Holst et al,
1981; Bremond et al, 1982; Jasonni et al, 1984; Gimes et al, 1986;
Petterson et al, 1986; Austin, 1991; Nyholm, 1993; Postischman,
1996). However, a limitation of these studies is that hormone
measurements were made in blood samples drawn after diagnosis,
and may have been influenced by the presence of the tumour. We
report here on a case–control study of endometrial cancer nested
within the New York University (NYU) Women’s Health Study, a
prospective cohort study of hormonal and environmental factors
and cancer in women (Toniolo et al, 1991, 1995). This study is, to
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gens and risk of endometrial cancer. We also examined the associ-
ation of body mass index with risk of endometrial cancer, and the
effect of adjusting for oestrogen levels on this association. 
MATERIAL AND METHODS 
The NYU Women’s Health Study 
Between 1985 and 1991, the NYU Women’s Health Study
enrolled 14 275 healthy women aged 34–65 years at the Guttman
Breast Diagnostic Institute, a breast cancer screening centre in
New York City (Toniolo et al, 1991, 1995). Among the 7054
cohort members who were postmenopausal at the time of enrol-
ment, 1641 had had a hysterectomy. The current report is limited
to the remaining 5413 postmenopausal participants. Women were
classified as postmenopausal at entry if they had had no menstrual
cycles during the 6 months preceding enrolment, or if they had had
a total bilateral oophorectomy. Women who had taken hormonal
medications in the 6 months preceding their visit were not eligible.
After written informed consent was obtained, demographic,
medical, anthropometric, reproductive, and dietary data were
collected through self-administered questionnaires. 30 millilitres
of non-fasting peripheral venous blood were drawn prior to breast
examination. After centrifugation, serum samples were divided
into 1 millilitre aliquots and immediately stored at –80˚C for
subsequent biochemical analyses. Up to 1991, women who
returned for annual breast cancer screening were invited to
contribute additional blood donations. 
Nested case–control study 
Cases of endometrial cancer were identified through active follow-
up of the cohort by mailed questionnaires every 2 years and tele-
phone interviews for non-respondents, as well as record linkage
with state cancer registries in New York, New Jersey, and
Connecticut, and with the National Death Index. A capture–
recapture analysis estimated that the ascertainment rate for breast
cancer in our cohort is 95% (Kato et al, 1999). Medical and
pathology reports were requested to confirm the diagnosis. Cases
diagnosed within 6 months of blood donation were excluded in
order to reduce the potential for observing differences in hormonal
concentrations due to the tumour growth. 
For each case subject, 4 controls were selected at random from
the risk set of women who were alive and free of disease at the
time of diagnosis of the case (index date), who had not had
hysterectomy prior to the index date, and who matched the case on
menopausal status at enrolment, date of birth (± 6 months), and
number (1, > 1) of blood donations. For women who gave blood
more than once samples from the second blood donation were
used, but only if the lagtime between second blood donation and
endometrial cancer diagnosis was at least 6 months. The policy of
the NYU Women’s Health Study is to use the second blood dona-
tion whenever possible to allow the first blood donation to be
preserved for future studies of other diseases which may have been
diagnosed between the first and second blood samplings. Controls
were matched to cases on the date of first blood donation (± 3
months) if the first serum sample was used, or second blood dona-
tion (± 3 months) otherwise. Relaxation criteria (date of birth ± 12
months and date of blood donation ± 6 months) were used if the
risk set for a case had less than 4 subjects. Both case and control
subjects who had reported breast cancer prior to the index date
were excluded because of the common use of tamoxifen in the
treatment of breast cancer and the well known increase in risk of
endometrial cancer associated with use of this therapeutic agent. 
Cases and controls were contacted by telephone to collect
detailed information on endometrial cancer risk factors. Data were
collected on medical history, smoking, oral contraceptive and
hormone replacement therapy use up to the index date. A calendar
to record reproductive life events and two photo booklets (one for
oral contraceptives and one for hormone replacement therapy)
were mailed to each participant prior to the interview. The Nurses’
Health Study photo booklet for oral contraceptives was used and a
photo booklet for hormone replacement therapy was developed
specifically for this study. Interviewers were unaware of the case
or control status of the interviewees. 
Laboratory analyses 
Percent oestradiol bound to SHBG was determined by a
Concanavalin A-agarose binding assay and percent oestradiol free
by an ultrafiltration method, as described previously (Toniolo et al,
1995). SHBG was quantified by a chemiluminescent immuno-
metric assay using immunolite technology (Diagnostic Products
Corp, Los Angeles, CA). The assays for total oestradiol and
oestrone were performed by the Clinical Studies Center of Quest
Diagnostics Inc (Nichols Institute, San Juan Capistrano, CA).
Serum samples were submitted to organic extraction and celite
chromatography and the appropriate fractions analysed by
radioimmunoassay (Abraham et al, 1970; Mikhail and Chung,
1970). The quantity of serum was insufficient to determine
oestrone levels for 8 women (1 case and 7 controls) and oestradiol
levels for 4 women (all controls). These women were excluded
from the analyses of the hormone for which they had missing data.
However, because most of them were controls and because a
matched set was composed of one case and 4 controls, no matched
set was excluded from the oestradiol analysis and only one
matched set was excluded from the oestrone analyses. In 11
samples, levels were below the detection limit of oestrone
(10 pg ml–1) and were arbitrarily set at 5 pg ml–1. For oestradiol,
the detection limit was 2 pg ml–1 and for SHBG 0.2 nmol ml–1;
none of the measurements were below these levels. 
Laboratory personnel were not aware of the case or control status
of the samples, and samples from a case and her matched controls
were analysed in the same batch. In order to assess laboratory preci-
sion, one aliquot from a common pool was included with every
other matched set after labelling to preclude identification. The
pool was generated using serum samples from a random sample
of the healthy postmenopausal NYU Women’s Health Study
participants. Intra-batch coefficients of variation were 4.8% for
total oestradiol, 9.5% for oestrone, 16.0% for percent free
oestradiol, 4.2% for percent oestradiol bound to SHBG, and 6.5%
for SHBG. The median storage time was 12.3 years (range,
8.3–13.8 years). 
Statistical methods 
Hormone and SHBG measurements were log-transformed to
reduce departures from the normal distribution with the exception
of percent free oestradiol and percent SHBG-bound oestradiol.
Case and control hormonal levels were compared using a mixed
effects linear regression model to take into account the matched
design (Liang and Zeger, 1986). 
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into tertiles, using the frequency distribution of the cases and the
controls combined. The data were analysed using conditional
logistic regression (Breslow and Day, 1980). Odds ratios were
computed relative to the lowest tertile. Likelihood ratio tests were
used to assess the significance of overall associations, linear trends
and deviations from linearity. Reported trend test P values corres-
pond to hormone and SHBG variables treated as ordered categor-
ical variables. Analyses were also performed on the continous
variables. All P values are two-sided. 
Because of the known association between obesity and
oestrogen levels, we conducted analyses adjusting for body mass
index assessed at time of blood donation. In these analyses, height
was also included in the models because it has been shown that, if
obesity is a risk factor, including only body mass index in a model
forces an inverse-quadratic relation of height to risk given weight
(Michels et al, 1998). The effect of other potential confounders
was explored by examining the association of these factors with
disease and hormone levels. The variations in the hormone regres-
sion coefficients induced by the addition of the potential
confounders in the logistic regression models were also examined.
Potential confounders considered were nulliparity (collected at
enrolment), history of diabetes, smoking history, oral contracept-
ive use and hormone replacement therapy use up to index date
(collected by telephone interviews). 
Logistic regression parameter estimates were corrected for
measurement error in the hormone and BMI variables using the
error-correction method of Armstrong et al (Armstrong et al, 1989)
for matched case–control data. Within-subject variance estimates
for percent oestradiol free, percent oestradiol bound to SHBG and
BMI were based on results from our previous reliability studies
(Sonnenschein et al, 1993; Toniolo et al, 1994). For log oestradiol
and log oestrone, estimates of within-subject variance were
provided by S Hankinson (personal communication, 2000). These
data came from a reliability study conducted in 79 healthy post-
menopausal Nurses’ Health Study participants who had given 3
annual blood samples (Hankinson et al, 1995). Assays were
conducted in the same laboratory as for our study, i.e. the Nichols
Institute. Error terms associated with each exposure variable were
assumed to be independent of each other, of the true value of the
exposure, and of measurement errors from other exposure vari-
ables. 
RESULTS 
By December 31, 1997, 63 participants postmenopausal at enrol-
ment had been diagnosed with endometrial cancer. Pathology
reports were obtained for 90% of the cases; tumour confirmation
came from the tumour registries for the remaining 10%. 4 cases
were excluded because they had been diagnosed with breast cancer
prior to endometrial cancer and 2 cases because of the histology of
their tumour (one leiomyosarcoma and one mesodermal mixed
tumour of the uterus). 80% of the tumours were endometrioid
carcinomas, 12% were papillary serous adenocarcinoma, and the
remainder were mucinous or could not be classified further due to
lack of specification on the pathology report. 6 of the controls origin-
ally selected were excluded (4 had been erroneously classified as
postmenopausal at entry and 2 had died before the index date).
One participant who was selected as a control became a case later
on and was included in both matched sets as recommended
when risk-set sampling is used (Lubin and Gail, 1984). As a result,
57 cases and 222 controls are included in the present report.
Relaxation criteria were used to select 15 (7%) of the controls.
Interviews were obtained for 235 participants, resulting in a
response rate of 84% (88% for cases and 83% for controls). For 18
of the participants (12 cases, i.e. 24%, and 6 controls, i.e. 3%) the
interview was completed by a surrogate. For 3 cases and 29
controls who had not completed the telephone interview, inform-
ation on some risk factors for endometrial cancer (history of
diabetes, smoking, oral contraceptive use, hormone replacement
therapy use) was available from a previous follow-up question-
naire. As a result, data were available on 53 cases (93%) and 213
controls (96%) for most risk factors. 
The median age at blood donation was 61.1 years and the
median age at diagnosis of endometrial cancer was 65.7 years
(Table 1). The median body mass index was significantly higher
(P < 0.01) for case participants (25.5 kg/m2) than for control
participants (24.7 kg/m2). Ever use of hormone replacement
therapy and history of diabetes were reported more often by case
than by control subjects whereas ever smoking was more common
in controls than in cases. These differences were not statistically
significant. One control and none of the cases reported total
bilateral oophorectomy prior to entering the study. 
Table 2 reports serum levels of oestrogens and SHBG. Total
oestradiol, percent free oestradiol, and oestrone were significantly
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Table 1 Characteristics of postmenopausal endometrial cancer case and control subjects, NYU Women’s Health Study,
1985–1997 
Cases (n = 57) Controls (n = 222) 
Age (years) at blood donation, median (range) 61.1 (45.2–66.0) 61.1 (44.0–67.1) 
Age (years) at diagnosis, median (range) 65.7 (47.7–75.3) 
Height (cm), median (range) 162.7 (147–183)  160.1 (147–178) 
Weight (kg)*, median (range) 67.2 (46.8–113.5) 63.6 (45.4–109.0) 
Body mass index (kg/m2)*, median (range) 25.8 (17.7–44.2) 24.7 (17.7–37.8) 
Nulliparous1, n (%) 12 (24%) 53 (26%) 
Ever used oestrogen or oestrogen + progestagen replacement therapy1, n (%) 17 (32%) 53 (25%) 
Ever used oestrogen alone replacement therapy1, n (%) 10 (20%) 30 (16%) 
Ever used oral contraceptives1, n (%) 8 (15%) 37 (17%) 
History of diabetes1, n (%) 6 (11%) 13 (6%) 
Ever smoker1, n (%) 21 (42%) 95 (52%) 
*P < 0.01. 1Data missing for some subjects. higher in case than in control subjects. In addition, SHBG and
percent SHBG-bound oestradiol were significantly lower in cases
than in controls. Odds ratios for endometrial cancer were consist-
ent with these results (Table 3). An increase in risk was observed
with higher levels of oestradiol (OR = 2.4 in the highest versus the
lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5
in highest tertile, P for trend < 0.001), and oestrone (OR = 3.9 in
highest tertile, P for trend < 0.001). A decrease in risk was
observed with higher levels of percent oestradiol bound to SHBG
(OR = 0.43 in highest tertile, P for trend = 0.03) and SHBG (OR =
0.39 in highest tertile, P for trend = 0.01). All these associations
were reduced after adjustment for body mass index and height.
The associations with oestradiol and percent oestradiol bound to
SHBG were no longer significant and the association with SHBG
was only marginally significant (Table 3). None of the tests 
for deviation from linearity was significant and results using
continuous variables were similar to results using tertiles. The
regression coefficients adjusted for height and body mass index
were 0.63 (standard error = 0.30, P value = 0.04) for log10 (oestra-
diol), 2.75 (standard error = 0.95, P value = 0.003) for percent free
oestradiol, –0.033 (standard error = 0.018, P value = 0.06) for
percent SHBG-bound oestradiol, 0.69 (standard error = 0.34, P
value = 0.04) for log10 (oestrone), and –0.56 (standard error = 0.34,
P value = 0.09) for SHBG, respectively. 
The effect of other potential confounders was explored. There
was a slightly lower proportion of ever smokers in cases (42%)
than in controls (52%), and a history of smoking was associated
with lower levels of oestradiol (6.4 pg ml–1 for ever smokers
versus 7.5 pg ml–1 for never smokers, P = 0.01) and higher levels
of SHBG (56.5 nMol l–1 for ever smokers versus 49.0 nMol l–1 for
never smokers, P = 0.01) in control subjects. However, adjusting
for smoking history had very little impact on the logistic regres-
sion coefficients associated with hormones and SHBG. For
instance the regression coefficient for oestradiol went from 0.58
(standard error 0.335) in the model adjusting for height and body
mass index to 0.56 (standard error 0.336) in the model in which
smoking was added. Other potential risk factors (nulliparity, use of
hormone replacement therapy, use of oral contraceptives, and
history of diabetes) showed no association with hormone and
SHBG levels, and had no material impact on the logistic regres-
sion coefficients for hormones and SHBG. Because of the lack of
evidence of confounding effects, and because adjusting for these
factors resulted in a smaller study size due to missing data on some
of the subjects, odds ratios adjusting only for height and body
mass index are presented. 
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Table 3 Odds ratios and 95% confidence intervals for endometrial cancer associated with levels of hormones and sex hormone-binding
globulin (SHBG) among postmenopausal women: NYU Women’s Health Study, 1985–1997 
No. cases (%) No. controls (%) Unadjusted OR1 (95% CI) Adjusted OR2 (95% CI) 
Oestradiol, pg ml–1
< 6 14 (24.6%) 77 (35.3%) 1.0 1.0 
6–8 16 (28.1%) 80 (36.7%) 1.1 (0.52–2.4) 1.0 (0.47–2.3) 
> 8 27 (47.4%) 61 (28.0%) 2.4 (1.1–4.9) 1.8 (0.75–4.2) 
P for trend 0.02 0.19 
Free oestradiol, % 
< 1.10 13 (22.8%) 78 (35.1%) 1.0 1.0 
1.10–1.28 13 (22.8%) 84 (37.8%) 1.1(0.44–2.4) 0.91 (0.38–2.2) 
> 1.28 31 (54.4%) 60 (27.0%) 3.5 (1.6–7.5) 2.8 (1.3–6.4) 
P for trend < 0.001 0.004 
SHBG-bound oestradiol, % 
< 35.26 25 (43.9%) 68 (30.6%) 1.0 1.0 
35.26–43.30 18 (31.6%) 76 (34.2%) 0.59 (0.28–1.2) 0.66 (0.31–1.4) 
> 43.30 14 (24.6%) 78 (35.1%) 0.43 (0.20–0.95) 0.60 (0.26–1.4) 
P for trend 0.03 0.22 
Oestrone, pg ml–1
< 20 10 (17.9%) 83 (38.6%) 1.0 1.0 
20–28 19 (33.9%) 76 (35.3%) 2.1 (0.9–4.8) 2.0 (0.9–4.7) 
> 28 27 (48.2%) 56 (26.0%) 3.9 (1.8–8.7) 3.2 (1.3–7.8) 
<0.001 0.008 
SHBG, nMol l–1
< 44.3 26 (45.6%) 67 (30.3%) 1.0 1.0 
44.3–64.4 18 (31.6%) 74 (33.5%) 0.60 (0.30–1.2) 0.67 (0.33–1.4) 
> 64.4 13 (22.8%) 80 (36.2%) 0.39 (0.18–0.84) 0.49 (0.22–1.1) 
P for trend 0.01 0.08 
1Except for matching factors. 2For In (height) and In (body mass index). 
Table 2 Median, 10th and 90th percentiles of serum levels of oestrogens
and SHBG in postmenopausal endometrial cancer case and controls
subjects, NYU Women’s Health Study, 1985–1997 
Cases (n = 57) Controls (n = 222) 
Total oestradiol**, pg ml–1 8 (4–22) 7 (4–12) 
Free oestradiol**, % 1.31 (0.94–1.50) 1.17 (0.95–1.44) 
SHBG-bound oestradiol**, % 36.7 (19.6–51.9)  39.5 (27.2–50.6) 
Oestrone**, pg ml–1 27 (14–59) 22 (12–38) 
SHBG*, nMol L–1 45.3 (21.4–95.2) 55.3 (31.2–92.9) 
*P = 0.05; ** P < 0.01. DISCUSSION 
The median lagtime between blood donation and diagnosis in our
study was 5.5 years (range 0.5–11.4 years). 47 (82%) of the
tumours were diagnosed at least 2 years after blood donation. To
our knowledge, this is the first prospective study to report on the
association of oestrogen levels with endometrial cancer risk.
Higher levels of oestrone, total oestradiol, and percent free oestra-
diol were associated with an increased risk, whereas higher levels
of SHBG and SHBG-bound oestradiol were associated with a
decreased risk. Although some of the associations were no longer
statistically significant after adjusting for height and body mass
index, trends remained in the same directions and the limited
sample size may have contributed to the loss of significance. 
All women were postmenopausal with a median age at blood
donation of 61 years (range 44–67 years), and the levels of oestro-
gens were in the low range expected in this age group (median
oestradiol in the control group: 7 pg ml–1, 10–90th percentiles,
4–12 pg ml–1). Our results are consistent with the prediction of
Key and Pike (Key and Pike, 1988) that an increase in risk would
be observed with higher oestrogen levels, within the physio-
logically low menopausal range of levels. 
Early case–control studies, involving limited numbers of cases,
showed inconsistent results (Aleem et al, 1976; Benjamin and
Deutsch, 1976; Judd et al, 1976, 1980; Nisker et al, 1980;
Davidson et al, 1981; von Holst et al, 1981; Bremond et al, 1982;
Jasonni et al, 1984; Gimes et al, 1986; Pettersson et al, 1986). 3
more recent and larger case–control studies have reported positive
associations with postmenopausal levels of oestrogens. In a study
of 168 cases and 334 controls (Austin et al, 1991), cases had statis-
tically significantly higher serum oestrone and oestradiol levels
than controls, while another study (Nyholm et al, 1993) reported
higher levels of oestradiol, free oestradiol and oestrone in 50 cases
than in 54 matched controls. The largest case–control study to date
(Potischman et al, 1996), conducted in 5 US geographic regions,
with 208 postmenopausal matched case–control pairs observed an
increased risk of endometrial cancer with higher levels of total
oestradiol (geometric mean in cases = 10.8 pg ml–1 versus 7.4 pg
ml–1 in controls), oestrone (geometric mean in cases = 43.7 pg ml–1
versus 33.1 pg ml–1 in cases), free oestradiol, albumin-bound
oestradiol, and oestrone sulphate. A trend of reduced risk was
observed with increasing levels of SHBG (geometric mean in
cases = 30.6 pg ml–1 versus 41.5 pg ml–1 in controls). 
The study of Potischman et al (1996) also reported a strong
association with obesity, with an odds ratio of 3.8 for a body mass
index of 30.0 kg/m2 or more compared with one lower than 23.0
kg/m2. The odds ratio was slightly reduced (to 3.1) but remained
significant after adjusting for oestrone levels and correcting for
measurement error (Potischman et al, 1999). This result was unex-
pected because body mass index is generally thought to play a role
in the development of endometrial cancer through increased
production of oestrogens via peripheral aromatization of andro-
gens. Its association with endometrial cancer risk would therefore
be expected to be substantially reduced when adjusting for
oestrogen levels, unless it acts through some other mechanisms. In
Table 4, we report the logistic regression coefficients for endome-
trial cancer associated with body mass index in an analysis similar
to that mentioned above (Potischman et al, 1999). Prior to adjust-
ment for hormone level, risk showed a significant positive associ-
ation with body mass index (conditional logistic regression
coefficient = 0.087, P = 0.007), this was substantially reduced and
no longer significant after adjusting for oestrone level (regression
coefficient = 0.051, P = 0.16). These results are similar to those of
Potischman et al with respect to the direction, but not the strength,
of the association: we found the association with body mass index
to be weaker (regression coefficient 0.051 versus 0.081), and with
oestrone stronger (regression coefficient 0.68 versus 0.44). In both
studies, correcting for measurement error resulted in an increase of
the oestrone coefficient and a small attenuation of the body mass
index coefficient. Although our results do not refute a role of body
mass index in endometrial cancer independently of its effect on
oestrogen levels, they do not provide the same support for this
hypothesis as the other study (Potischman et al, 1999). 
A limitation of our study is that data on use of oral contracept-
ives and hormone replacement therapy, 2 factors strongly associ-
ated with endometrial cancer risk and therefore potential
confounders, were collected after diagnosis of the cases, raising
the concern of recall bias. In addition, for deceased participants,
telephone interviews were completed by surrogates who may not
have had accurate information about these exposures. Because
more case than control interviews were completed by surrogates,
differential misclassification may have resulted. For a factor to
confound an association, though, it needs to be associated with the
exposures of interest, here postmenopausal oestrogen and SHBG
levels, in addition to being associated with disease. Women who
use hormone replacement therapy tend to be leaner, suggesting
that they may have lower oestrogen levels than women who do not
use them (Derby et al, 1993). However, in our dataset there was no
evidence of a difference in age-adjusted levels of sex hormones 
or SHBG between control subjects who had and had not used
hormone replacement therapy. For instance, for oestradiol
geometric means were 7.2 pg ml–1 in users and 6.7 in nonusers
(P = 0.17); for oestrone the geometric means were 20.4 pg ml–1
and 21.5 pg ml–1 in users and nonusers respectively (P = 0.50).
Regarding oral contraceptive use, there are no data to suggest
an association with subsequent postmenopausal endogenous
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Table 4 Logistic regression coefficients for endometrial cancer associated with In (oestrone) and body mass index in the NYU Women’s
Health Study and the Potischman et al study (Potischman et al, 1999) 
NYU Women’s Health Study Potischman et al study 
Unadjusted Adjusted1 Adjusted and corrected2 Adjusted1 Adjusted and corrected2
In (oestrone) 0.88 0.68 0.81 0.44 0.62 
Body mass index 0.087 0.051 0.048 0.081 0.075 
1Adjusted for the other variable in the table. 2Adjusted for the other variable in the table and corrected for measurement error. oestrogen levels. These results suggest that confounding by these
factors was unlikely in our study. It should be noted that the preva-
lence of both oral contraceptive use and hormone replacement
therapy were low in our cohort because women who had used
either one of these in the 6 months preceding enrolment were not
eligible. The major strength of our study is that the serum samples
used for hormone measurements were collected prior to disease
and that no selection bias was operating because these measure-
ments were available on all cases and controls. 
There is increasing evidence that oestrogen may be associated
only with some types of endometrial cancer, i.e. endometrioid
adenocarcinomas, also called type I carcinomas. Type II carci-
nomas that include serous carcinomas and some other aggressive
types are observed in older women, develop from atrophic rather
than hyperplastic epithelium and do not appear to be related to
oestrogen exposure (Sherman, 2000). Because of the limited
sample size of our study and the lack of specification of some of
the pathology reports, we were not able to examine separately the
different histopathologic types. Future epidemiologic studies
should do so, although the lack of standardization of pathological
reporting and the relatively small proportion of type II carcinomas
(approximately 20%), may hamper such efforts. 
In conclusion, postmenopausal levels of oestrone, total oestra-
diol, and percent-free oestradiol, measured 6 months to 11 years
prior to diagnosis, were positively associated with risk of endome-
trial cancer in our study. SHBG and percent SHBG-bound oestra-
diol were negatively associated with risk. Body mass index did not
seem to be associated with risk of endometrial cancer after
adjusting for oestrone levels. 
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